Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus (Translational Psychiatry, (2016), 5, e642, 10.1038/tp.2015.145);Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus

Translational Psychiatry

Volumn 5, Issue 9, 2015, Pages

  Kroeze, Y ^a,b   Peeters, D ^a   Boulle, F ^c   Van Den Hove, D L A ^c   Van Bokhoven, H ^b   Zhou, H ^b,d   Homberg, J R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE 1; ADRENOCEPTOR BETA 2; BETA ADRENERGIC RECEPTOR; CASPASE 8; CILIARY NEUROTROPHIC FACTOR; CLAUDIN 11; FLUOXETINE; HOMEODOMAIN PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; NEUROTENSIN; NK6 HOMEOBOX 2; OCTAMER TRANSCRIPTION FACTOR 6; OLFACTOMEDIN 1; PROTEIN KINASE C DELTA; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTOME; TRANSFERRIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 3; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 488; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; EXPERIMENTAL ANXIETY TEST; GENE EXPRESSION REGULATION; GENE ONTOLOGY; HIPPOCAMPAL TISSUE; LONG TERM CARE; MALE; MYELINATION; NEWBORN; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; RAT; RATTUS NORVEGICUS; SEROTONIN UPTAKE INHIBITOR SENSITIVE ANXIETY TEST; TRANSCRIPTOMICS; UPREGULATION; ANIMAL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; HIPPOCAMPUS; LONG TERM ADVERSE EFFECTS; METABOLISM; NERVE CONDUCTION; PATHOLOGY; PHARMACOGENETICS;

ANIMALS; BEHAVIOR, ANIMAL; CILIARY NEUROTROPHIC FACTOR; FLUOXETINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIPPOCAMPUS; LONG TERM ADVERSE EFFECTS; NEURAL CONDUCTION; PHARMACOGENETICS; RATS; SEROTONIN UPTAKE INHIBITORS; TRANSFERRIN; UP-REGULATION;

EID: 84977763368     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.60     Document Type: Erratum

References (104)

1. Olivier JD, Blom T, Arentsen T, Homberg JR. The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1400-1408.
2. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005; CD004185.
3. Cristancho MA, Thase ME. Drug safety evaluation of olanzapine/fluoxetine combination. Expert Opin Drug Saf 2014; 13: 1133-1141.
4. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am 2014; 37: 375-391.
5. Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 2011; 13: 423-437.
6. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54: 1081-1088.
7. Doyle CA, McDougle CJ. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci 2012; 14: 263-279.
8. Makkonen I, Kokki H, Kuikka J, Turpeinen U, Riikonen R. Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism. Neuropediatrics 2011; 42: 207-209.
9. Khazaie H, Rezaie L, Rezaei Payam N, Najafi F. Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone; a randomized controlled trial. Gen Hosp Psychiatry 2015; 37: 40-45.
10. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20: 533-559.
11. Zou C, Ding X, Flaherty JH, Dong B. Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients. Neuropsychiatr Dis Treat 2013; 9: 1661-1670.
12. Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 2014; 29: 185-196.
13. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL. Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs 2002; 16: 425-434.
14. Okada F, Okajima K. Violent acts associated with fluvoxamine treatment. J Psychiatry Neurosci 2001; 26: 339-340.
15. Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law. PLoS Med 2006; 3: e372.
16. Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. Prim Care Companion J Clin Psychiatry 2001; 3: 168-174.
17. Altshuler L, Suppes T, Black D, Nolen WA, Keck PE Jr, Frye MA et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 1252-1262.
18. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270-1278.
19. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002; 59: 1111-1118.
20. Flint AJ, Rifat SL. Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry 1999; 156: 943-945.
21. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-522.
22. Cremers TI, Giorgetti M, Bosker FJ, Hogg S, Arnt J, Mork A et al. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 2004; 29: 1782-1789.
23. Cremers TI, Rea K, Bosker FJ, Wikstrom HV, Hogg S, Mork A et al. Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies. Neuropsychopharmacology 2007; 32: 1550-1557.
24. Yamada J, Sugimoto Y. Effects of 5-HT(2) receptor antagonists on the antiimmobility effects of imipramine in the forced swimming test with mice. Eur J Pharmacol 2001; 427: 221-225.
25. Mnie-Filali O, Lambas-Senas L, Zimmer L, Haddjeri N. 5-HT7 receptor antagonists as a new class of antidepressants. Drug News Perspect 2007; 20: 613-618.
26. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1 A antagonists. Trends Neurosci 1996; 19: 378-383.
27. Portella MJ, de Diego-Adelino J, Ballesteros J, Puigdemont D, Oller S, Santos B et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011; 72: 962-969.
28. Guptarak J, Sarkar J, Hiegel C, Uphouse L. Role of 5-HT(1 A) receptors in fluoxetine-induced lordosis inhibition. Horm Behav 2010; 58: 290-296.
29. Shelton J, Bonaventure P, Li X, Yun S, Lovenberg T, Dugovic C. 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1 A receptor. Neuropharmacology 2009; 56: 448-454.
30. Monaca C, Boutrel B, Hen R, Hamon M, Adrien J. 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 2003; 28: 850-856.
31. Tanaka M, Kobayashi D, Murakami Y, Ozaki N, Suzuki T, Iwata N et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008; 11: 261-267.
32. Nonogaki K, Ohba Y, Wakameda M, Tamari T. Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of betaendorphin gene. Int J Neuropsychopharmacol 2009; 12: 547-552.
33. Nonogaki K, Nozue K, Takahashi Y, Yamashita N, Hiraoka S, Kumano H et al. Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors. Int J Neuropsychopharmacol 2007; 10: 675-681.
34. Kroeze Y, Zhou H, Homberg JR. The genetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2012; 136: 375-400.
35. Alme MN, Wibrand K, Dagestad G, Bramham CR. Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNFinduced long-term potentiation. Neural Plast 2007; 2007: 26496.
36. Barbon A, Popoli M, La VL, Moraschi S, Vallini I, Tardito D et al. Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol Psychiatry 2006; 59: 713-720.
37. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011; 68: 1104-1112.
38. El Marroun H, White TJ, van der Knaap NJ, Homberg JR, Fernandez G, Schoemaker NK et al. Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children. Br J Psychiatry 2014; 205: 95-102.
39. Zimmerberg B, Germeyan SC. Effects of neonatal fluoxetine exposure on behavior across development in rats selectively bred for an infantile affective trait. Dev Psychobiol 2015; 57: 141-152.
40. Simpson KL, Weaver KJ, de Villers-Sidani E, Lu JY, Cai Z, Pang Y et al. Perinatal antidepressant exposure alters cortical network function in rodents. Proc Natl Acad Sci USA 2011; 108: 18465-18470.
41. Kinast K, Peeters D, Kolk SM, Schubert D, Homberg JR. Genetic and pharmacological manipulations of the serotonergic system in early life: neurodevelopmental underpinnings of autism-related behavior. Front Cell Neurosci 2013; 7: 72.
42. Olivier JD, Valles A, van HF, frasiab-Middelman A, Roelofs JJ, Jonkers M et al. Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. Psychopharmacology (Berl) 2011; 217: 419-432.
43. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004; 306: 879-881.
44. Popa D, Lena C, Alexandre C, Adrien J. Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J Neurosci 2008; 28: 3546-3554.
45. Hansen HH, Mikkelsen JD. Long-term effects on serotonin transporter mRNA expression of chronic neonatal exposure to a serotonin reuptake inhibitor. Eur J Pharmacol 1998; 352: 307-315.
46. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG et al. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999; 19: 10494-10501.
47. Homberg JR, De Boer SF, Raaso HS, Olivier JD, Verheul M, Ronken E et al. Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology (Berl) 2008; 200: 367-380.
48. Hensler JG. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 2003; 72: 1665-1682.
49. Witteveen JS, Middelman A, van Hulten JA, Martens GJ, Homberg JR, Kolk SM. Lack of serotonin reuptake during brain development alters rostral rapheprefrontal network formation. Front Cell Neurosci 2013; 7: 143.
50. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003; 4: 1002-1012.
51. Riccio O, Potter G, Walzer C, Vallet P, Szabo G, Vutskits L et al. Excess of serotonin affects embryonic interneuron migration through activation of the serotonin receptor 6. Mol Psychiatry 2009; 14: 280-290.
52. Miceli S, Negwer M, van Eijs F, Kalkhoven C, van Lierop I, Homberg J et al. High serotonin levels during brain development alter the structural input-output connectivity of neural networks in the rat somatosensory layer IV. Front Cell Neurosci 2013; 7: 88.
53. Fan Q, Yan X, Wang J, Chen Y, Wang X, Li C et al. Abnormalities of white matter microstructure in unmedicated obsessive-compulsive disorder and changes after medication. PLoS One 2012; 7: e35889.
54. Rayen I, Gemmel M, Pauley G, Steinbusch HW, Pawluski JL. Developmental exposure to SSRIs, in addition to maternal stress, has long-term sex-dependent effects on hippocampal plasticity. Psychopharmacology (Berl) 2014; 232: 1231-1244.
55. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-9110.
56. Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci USA 2001; 98: 12320-12322.
57. Engin E, Treit D. The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol 2007; 18: 365-374.
58. Cominski TP, Jiao X, Catuzzi JE, Stewart AL, Pang KC. The role of the hippocampus in avoidance learning and anxiety vulnerability. Front Behav Neurosci 2014; 8: 273.
59. Frey BN, Andreazza AC, Nery FG, Martins MR, Quevedo J, Soares JC et al. The role of hippocampus in the pathophysiology of bipolar disorder. Behav Pharmacol 2007; 18: 419-430.
60. Zetzsche T, Preuss UW, Frodl T, Schmitt G, Seifert D, Munchhausen E et al. Hippocampal volume reduction and history of aggressive behaviour in patients with borderline personality disorder. Psychiatry Res 2007; 154: 157-170.
61. Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 2004; 29: 417-426.
62. Homberg JR, Olivier JD, Blom T, Arentsen T, van BC, Schipper P et al. Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One 2011; 6: e16646.
63. Thompson MR, Li KM, Clemens KJ, Gurtman CG, Hunt GE, Cornish JL et al. Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. Neuropsychopharmacology 2004; 29: 694-704.
64. Miyamoto D, Iijima M, Yamamoto H, Nomura H, Matsuki N. Behavioural effects of antidepressants are dependent and independent on the integrity of the dentate gyrus. Int J Neuropsychopharmacol 2011; 14: 967-976.
65. Eitan R, Landshut G, Lifschytz T, Einstein O, Ben-Hur T, Lerer B. The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: possible role in antidepressant-augmenting properties. Int J Neuropsychopharmacol 2010; 13: 553-561.
66. Zhu XH, Yan HC, Zhang J, Qu HD, Qiu XS, Chen L et al. Intermittent hypoxia promotes hippocampal neurogenesis and produces antidepressant-like effects in adult rats. J Neurosci 2010; 30: 12653-12663.
67. Shan L, Schipper P, Nonkes LJ, Homberg JR. Impaired fear extinction as displayed by serotonin transporter knockout rats housed in open cages is disrupted by IVC cage housing. PLoS One 2014; 9: e91472.
68. Schipper P, Nonkes LJ, Karel P, Kiliaan AJ, Homberg JR. Serotonin transporter genotype x construction stress interaction in rats. Behav Brain Res 2011; 223: 169-175.
69. Pawluski JL, Rayen I, Niessen NA, Kristensen S, van Donkelaar EL, Balthazart J et al. Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience 2012; 220: 131-141.
70. Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, Scherer S et al. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004; 428: 493-521.
71. Crestani CC, Tavares RF, Guimaraes FS, Correa FM, Joca SR, Resstel LB. Chronic fluoxetine treatment alters cardiovascular functions in unanesthetized rats. Eur J Pharmacol 2011; 670: 527-533.
72. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009; 34: 2459-2468.
73. Samuels BA, Leonardo ED, Dranovsky A, Williams A, Wong E, Nesbitt AM et al. Global state measures of the dentate gyrus gene expression system predict antidepressant-sensitive behaviors. PLoS One 2014; 9: e85136.
74. Moore CS, Abdullah SL, Brown A, Arulpragasam A, Crocker SJ. How factors secreted from astrocytes impact myelin repair. J Neurosci Res 2011; 89: 13-21.
75. Bronstein JM. Function of tetraspan proteins in the myelin sheath. Curr Opin Neurobiol 2000; 10: 552-557.
76. Birling MC, Tait S, Hardy RJ, Brophy PJ. A novel rat tetraspan protein in cells of the oligodendrocyte lineage. J Neurochem 1999; 73: 2600-2608.
77. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 2005; 10: 309-322.
78. Boulle F, Pawluski JL, Homberg JR, Machiels B, Kroeze Y, Kumar N et al. Developmental fluoxetine exposure increases depressive-related behavior and alters epigenetic regulation of the hippocampal BDNF gene in prenatally stressed female offspring. Submitted.
79. Jungke P, Ostrow G, Li JL, Norton S, Nieber K, Kelber O et al. Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John's wort extract (STW 3-VI) and fluoxetine. Psychopharmacology (Berl) 2011; 213: 757-772.
80. Lee JH, Ko E, Kim YE, Min JY, Liu J, Kim Y et al. Gene expression profile analysis of genes in rat hippocampus from antidepressant treated rats using DNA microarray. BMC Neurosci 2010; 11: 152.
81. O'Connor RM, Grenham S, Dinan TG, Cryan JF. microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. Int J Neuropsychopharmacol 2013; 16: 1885-1892.
82. Deoni SC, Zinkstok JR, Daly E, Ecker C, Consortium MA, Williams SC et al. Whitematter relaxation time and myelin water fraction differences in young adults with autism. Psychol Med 2015; 45: 795-805.
83. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008; 31: 361-370.
84. Ito Y, Wiese S, Funk N, Chittka A, Rossoll W, Bommel H et al. Sox10 regulates ciliary neurotrophic factor gene expression in Schwann cells. Proc Natl Acad Sci USA 2006; 103: 7871-7876.
85. Chow E, Mottahedeh J, Prins M, Ridder W, Nusinowitz S, Bronstein JM. Disrupted compaction of CNS myelin in an OSP/Claudin-11 and PLP/DM20 double knockout mouse. Mol Cell Neurosci 2005; 29: 405-413.
86. De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004; 128: 597-604.
87. Fan LW, Bhatt A, Tien LT, Zheng B, Simpson KL, Lin RC et al. Exposure to serotonin adversely affects oligodendrocyte development and myelination in vitro. J Neurochem 2014; 133: 532-543.
88. Barres BA, Burne JF, Holtmann B, Thoenen H, Sendtner M, Raff MC. Ciliary neurotrophic factor enhances the rate of oligodendrocyte generation. Mol Cell Neurosci 1996; 8: 146-156.
89. Louis JC, Magal E, Takayama S, Varon S. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science 1993; 259: 689-692.
90. Mayer M, Bhakoo K, Noble M. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development 1994; 120: 143-153.
91. Yokota H, Yoshikawa M, Hirabayashi H, Nakase H, Uranishi R, Nishimura F et al. Expression of ciliary neurotrophic factor (CNTF), CNTF receptor alpha (CNTFRalpha) following experimental intracerebral hemorrhage in rats. Neurosci Lett 2005; 377: 170-175.
92. Kang SS, Keasey MP, Arnold SA, Reid R, Geralds J, Hagg T. Endogenous CNTF mediates stroke-induced adult CNS neurogenesis in mice. Neurobiol Dis 2012; 49C: 68-78.
93. Salehi Z, Hadiyan SP, Navidi R. Ciliary neurotrophic factor role in myelin oligodendrocyte glycoprotein expression in Cuprizone-induced multiple sclerosis mice. Cell Mol Neurobiol 2013; 33: 531-535.
94. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A et al. Genomewide atlas of gene expression in the adult mouse brain. Nature 2007; 445: 168-176.
95. Muller S, Chakrapani BP, Schwegler H, Hofmann HD, Kirsch M. Neurogenesis in the dentate gyrus depends on ciliary neurotrophic factor and signal transducer and activator of transcription 3 signaling. Stem Cells 2009; 27: 431-441.
96. Hertz L, Rothman DL, Li B, Peng L. Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift. Front Behav Neurosci 2015; 9: 25.
97. Albrecht PJ, Enterline JC, Cromer J, Levison SW. CNTF-activated astrocytes release a soluble trophic activity for oligodendrocyte progenitors. Neurochem Res 2007; 32: 263-271.
98. Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J Neurosci 2002; 22: 9221-9227.
99. Peruga I, Hartwig S, Merkler D, Thone J, Hovemann B, Juckel G et al. Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior. Behav Brain Res 2012; 229: 325-332.
100. Morita K, Sasaki H, Fujimoto K, Furuse M, Tsukita S. Claudin-11/OSP-based tight junctions of myelin sheaths in brain and Sertoli cells in testis. J Cell Biol 1999; 145: 579-588.
101. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362: 798-805.
102. Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castren E. Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 2009; 19: 97-108.
103. Ko MC, Lee LJ, Li Y, Lee LJ. Long-term consequences of neonatal fluoxetine exposure in adult rats. Dev Neurobiol 2014; 74: 1038-1051.
104. Yune TY, Lee JY, Kang S. Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. J Neurotrauma 2015; 32: 633-644.